Amersham Biosciences Collaborates with BioDiscovery for Software Development
Amersham Biosciences has announced an agreement with BioDiscovery Inc. to co-develop and commercialize software for the automated analysis of Amersham Biosciences’ CodeLink Bioarrays. Amersham Biosciences acquired the rights to this software through the acquisition of the CodeLink business in July, 2002. The CodeLink System is an integrated bioarray platform capable of high performance gene expression and single nucleotide polymorphism (SNP) analysis.
Using software already developed by BioDiscovery for the CodeLink System, the agreement brings together the performance of Amersham Biosciences’ CodeLink(tm) bioarrays with BioDiscovery’s patented software solutions for microarrays. This combination will assist researchers in uncovering low expressing genes typically not discernible on other platforms. In addition, use of the BioDiscovery software allows transition to higher density arrays when available.
“The CodeLink system provides our customers with the highest possible quality through the high sensitivity and reproducibility of our array products,” said Martin Tricarico, VP Business Development, Genomics, Amersham Biosciences. “Now, with a key software partner in BioDiscovery, we’ve also optimized the data extraction from our CodeLink arrays. This enables us to provide customers with optimal accuracy and data quality in a high throughput solution.”
“This partnership ensures that users of Amersham Biosciences’ CodeLink bioarrays will have access to image analysis software that has been specially customized to extract high quality information from CodeLink bioarrays in a high throughput, automated process”, said Greg Moore, Vice President Business Development, BioDiscovery, Inc.